<DOC>
	<DOCNO>NCT01103713</DOCNO>
	<brief_summary>The study conduct asymptomatic pregnant woman P. falciparum parasitemia . The subject give 3 day dose regiment fixed-dose combination Azithromycin Chloroquine . Parasitological clearance rate polymerase chain reaction data evaluate Day 28 primary endpoint .</brief_summary>
	<brief_title>Evaluate Parasitological Clearance Rates And Pharmacokinetics Of The Combination Of Azithromycin And Chloroquine In Asymptomatic Pregnant Women With Falciparum Parasitemia In Africa</brief_title>
	<detailed_description>After interim analysis efficacy data External Data Monitoring Committee , study terminate . Investigators notify 22 Aug 2013 . There safety concern lead termination .</detailed_description>
	<mesh_term>Parasitemia</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<criteria>Primigravidae secundigravidae pregnant woman &gt; =14 &lt; =30 week gestational age ( confirm ultrasound examination ) . Evidence asymptomatic parasitemia Plasmodium falciparum monoinfection ( confirm microscopy ) parasite count range 80 100,000/uL thick blood smear . Evidence personally sign date informed consent document indicate subject ( legally acceptable representative subject &lt; 18 year age ) inform pertinent aspect study question subject sufficiently answer . Assent obtain subject &lt; 18 year age . Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure . Age &lt; 16 year old &gt; 35 year old . Multiple gestation ( one fetus ) per ultrasound result screen . Clinical symptom malaria . Hemoglobin &lt; 8 g/dL ( measure baseline ) . Any condition require hospitalization evidence severe concomitant infection time presentation . Use antimalarial drug previous 4 week . History convulsion , hypertension , diabetes chronic illness may adversely affect fetal growth viability . Known allergy study drug ( AZ , CQ , SP ) macrolides sulphonamides . Requirement use medication study might interfere evaluation study drug AZ CQ contra indicate pregnancy per package insert . Severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study . Evidence current obstetric complication may adversely impact pregnancy and/or fetal outcome , include presence congenital anomaly , placenta previa abruption . Known severe sickle cell ( SS ) disease sickle hemoglobin C ( SC ) anemia . Known family history prolong QT syndrome , serious ventricular arrhythmia , sudden cardiac death .</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>P. falciparum malaria</keyword>
	<keyword>asymptomatic parasitemia</keyword>
	<keyword>parasitological clearance</keyword>
	<keyword>Intermittent Preventive Treatment Falciparum Malaria Pregnant Women ( IPTp )</keyword>
</DOC>